CYTOKINETICS, INCORPORATED Share-based Payment Arrangement, Expense
CYTOKINETICS, INCORPORATED (CYTK) reported Share-based Payment Arrangement, Expense of $35.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED share-based payment arrangement, expense for the quarter ending 2026-06-30 was $35.71M, a 29.69% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, expense for the quarter ending 2026-03-31 was $30.39M, a 29.07% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, expense for the quarter ending 2025-12-31 was $30.51M, a 16.21% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, expense for the quarter ending 2025-09-30 was $30.70M, a 21.06% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, expense for fiscal 2025 was $112.29M, a 14.76% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, expense for fiscal 2024 was $97.84M, a 35.77% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, expense for fiscal 2023 was $72.06M, a 50.60% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, expense for fiscal 2022 was $47.85M, a 78.34% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 1 month | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $35.71M 10-Q · filed 2026-08-06 | $66.11M 10-Q · filed 2026-08-06 | $96.61M derived: sum of 3 quarters · filed 2026-08-06 | $127.31M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $30.39M 10-Q · filed 2026-05-05 | $60.90M derived: sum of 2 quarters · filed 2026-05-05 | $91.60M derived: sum of 3 quarters · filed 2026-05-05 | $119.13M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $30.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $61.20M derived: sum of 2 quarters · filed 2026-02-26 | $88.74M derived: sum of 3 quarters · filed 2026-08-06 | $112.29M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $30.70M 10-Q · filed 2025-11-05 | $58.23M derived: sum of 2 quarters · filed 2026-08-06 | $81.78M 10-Q · filed 2025-11-05 | $108.03M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $27.54M 10-Q · filed 2026-08-06 | $51.08M 10-Q · filed 2026-08-06 | $77.33M derived: sum of 3 quarters · filed 2026-08-06 | $102.69M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $23.55M 10-Q · filed 2026-05-05 | $49.80M derived: sum of 2 quarters · filed 2026-05-05 | $75.16M derived: sum of 3 quarters · filed 2026-05-05 | $99.78M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $26.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $51.61M derived: sum of 2 quarters · filed 2026-02-26 | $76.23M derived: sum of 3 quarters · filed 2026-02-26 | $97.84M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $25.36M 10-Q · filed 2025-11-05 | $49.98M derived: sum of 2 quarters · filed 2025-11-05 | $71.59M 10-Q · filed 2025-11-05 | $91.08M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $24.62M 10-Q · filed 2025-08-07 | $46.23M 10-Q · filed 2025-08-07 | $65.72M derived: sum of 3 quarters · filed 2026-02-26 | $84.44M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $21.61M 10-Q · filed 2025-05-06 | $21.60M 10-Q · filed 2024-05-10 | $41.10M derived: sum of 2 quarters · filed 2026-02-26 | $59.81M derived: sum of 3 quarters · filed 2026-02-26 | $78.48M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $19.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $38.20M derived: sum of 2 quarters · filed 2026-02-26 | $56.87M derived: sum of 3 quarters · filed 2026-02-26 | $72.06M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $18.72M 10-Q · filed 2024-11-07 | $18.70M 10-Q · filed 2023-11-03 | $37.38M derived: sum of 2 quarters · filed 2024-11-07 | $52.58M 10-Q · filed 2024-11-07 | $52.60M 10-Q · filed 2023-11-03 | $66.04M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $18.67M 10-Q · filed 2024-08-09 | $18.70M 10-Q · filed 2023-08-03 | $33.86M 10-Q · filed 2024-08-09 | $33.90M 10-Q · filed 2023-08-03 | $47.32M derived: sum of 3 quarters · filed 2025-02-27 | $60.52M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $15.20M 10-Q · filed 2024-05-10 | $28.65M derived: sum of 2 quarters · filed 2025-02-27 | $41.85M derived: sum of 3 quarters · filed 2025-02-27 | $54.05M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $13.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $26.65M derived: sum of 2 quarters · filed 2025-02-27 | $38.85M derived: sum of 3 quarters · filed 2025-02-27 | $47.85M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $13.20M 10-Q · filed 2023-11-03 | $25.40M derived: sum of 2 quarters · filed 2023-11-03 | $34.40M 10-Q · filed 2023-11-03 | |||||
| 2022-06-30 | $12.20M 10-Q · filed 2023-08-03 | $21.20M 10-Q · filed 2023-08-03 | ||||||
| 2022-03-31 | $9.00M 10-Q · filed 2023-05-05 | |||||||
| 2021-12-31 | $26.83M 10-K · filed 2024-02-28 | |||||||
| 2020-12-31 | $17.62M 10-K · filed 2023-03-01 | |||||||
| 2019-12-31 | $10.76M 10-K · filed 2022-02-25 | |||||||
| 2018-12-31 | $9.76M 10-K · filed 2021-02-26 | |||||||
| 2017-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $4.83M derived: sum of 2 quarters · filed 2019-03-07 | $7.03M derived: sum of 3 quarters · filed 2019-03-07 | $9.03M 10-K · filed 2019-03-07 | ||||
| 2017-09-30 | $2.40M 10-Q · filed 2017-11-03 | $4.60M derived: sum of 2 quarters · filed 2017-11-03 | $6.60M 10-Q · filed 2017-11-03 | $8.35M derived: sum of 4 quarters · filed 2018-03-05 | ||||
| 2017-06-30 | $2.20M 10-Q · filed 2017-08-04 | $4.10M 10-Q · filed 2017-08-04 | $5.95M derived: sum of 3 quarters · filed 2018-03-05 | $7.85M derived: sum of 4 quarters · filed 2018-03-05 | ||||
| 2017-03-31 | $1.90M 10-Q · filed 2017-05-04 | $3.75M derived: sum of 2 quarters · filed 2018-03-05 | $5.65M derived: sum of 3 quarters · filed 2018-03-05 | $7.45M derived: sum of 4 quarters · filed 2018-03-05 | ||||
| 2016-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $3.75M derived: sum of 2 quarters · filed 2018-03-05 | $5.55M derived: sum of 3 quarters · filed 2018-03-05 | $7.15M 10-K · filed 2018-03-05 | ||||
| 2016-09-30 | $1.90M 10-Q · filed 2017-11-03 | $3.70M derived: sum of 2 quarters · filed 2017-11-03 | $5.30M 10-Q · filed 2017-11-03 | $6.67M derived: sum of 4 quarters · filed 2018-03-05 | ||||
| 2016-06-30 | $1.80M 10-Q · filed 2017-08-04 | $3.40M 10-Q · filed 2017-08-04 | $4.77M derived: sum of 3 quarters · filed 2018-03-05 | $5.87M derived: sum of 4 quarters · filed 2018-03-05 | ||||
| 2016-03-31 | $1.60M 10-Q · filed 2017-05-04 | $1.60M 10-Q · filed 2016-05-05 | $2.97M derived: sum of 2 quarters · filed 2018-03-05 | $4.07M derived: sum of 3 quarters · filed 2018-03-05 | $5.27M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2015-12-31 | $1.37M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-05 | $2.47M derived: sum of 2 quarters · filed 2018-03-05 | $3.67M derived: sum of 3 quarters · filed 2018-03-05 | $4.57M 10-K · filed 2018-03-05 | ||||
| 2015-09-30 | $1.10M 10-Q/A · filed 2016-12-15 | $2.30M derived: sum of 2 quarters · filed 2016-12-15 | $3.20M 10-Q/A · filed 2016-12-15 | $4.13M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2015-06-30 | $1.20M 10-Q · filed 2016-08-04 | $2.10M 10-Q · filed 2016-08-04 | $3.03M derived: sum of 3 quarters · filed 2017-03-06 | $3.93M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2015-03-31 | $900.00K 10-Q · filed 2016-05-05 | $1.83M derived: sum of 2 quarters · filed 2017-03-06 | $2.73M derived: sum of 3 quarters · filed 2017-03-06 | $3.63M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2014-12-31 | $930.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $1.83M derived: sum of 2 quarters · filed 2017-03-06 | $2.73M derived: sum of 3 quarters · filed 2017-03-06 | $3.33M 10-K · filed 2017-03-06 | ||||
| 2014-09-30 | $900.00K 10-Q · filed 2015-11-05 | $1.80M derived: sum of 2 quarters · filed 2015-11-05 | $2.40M 10-Q · filed 2015-11-05 | |||||
| 2014-06-30 | $900.00K 10-Q · filed 2015-08-05 | $1.60M 10-Q · filed 2015-08-05 | ||||||
| 2014-03-31 | $700.00K 10-Q · filed 2015-05-04 | |||||||
| 2013-12-31 | $3.60M 10-K · filed 2016-03-03 | |||||||
| 2012-12-31 | $3.78M 10-K · filed 2015-03-06 | |||||||
| 2011-12-31 | $3.07M 10-K · filed 2014-03-07 | |||||||
| 2010-12-31 | $4.02M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |